25 Dividend Giants Widely Held By ETFs
By The Online Investor Staff, updated Fri., Jan. 22, 4:17 PM
| This Slide: #1 of 25 |
#25. Gilead Sciences Inc (NASDAQ:GILD) — 4.06% Yield
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory and fibrotic diseases and oncology. Co.'s products include: Biktarvy for the treatment of HIV-1 infection in certain patients; Vosevi®, a single tablet regimen of sofosbuvir, velpatasvir and voxilaprevir for the re-treatment of chronic hepatitis C virus infection in adults; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; and Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Gilead Sciences SEC Filing Email Alerts Service
Open the GILD Page at The Online Investor »
|
||||||||||||||||||||||||
Open the GILD Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
  
|
Buy (2.79 out of 4) 20th percentile
(ranked lower than approx. 80% of all stocks covered)
Analysts' Target Price: GILD Stock Forecast Based on Zacks ABR data; powered by Xignite |
